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treatment; 1 had an ileostomy. Two patients (25%) required 
prolonged admission, 1 was admitted to critical care with 
neutropenic colitis. Capecitabine was discontinued in 6/8 
(75%); 5 (63%) required a break in XRT. Two patients (25%) 
discontinued XRT altogether. Mean small bowel V45 for 
patients who did and did not develop G3 toxicity was 38.6 
cm3 (range 0 – 178.8) and 113.0 cm3 (38.4 – 222.4) 
respectively. Two patients had a small bowel V45 >195 cm3, 
both developed G3 bowel toxicity. 
 
Conclusion: In this series, incidence of G3 bowel toxicity in 
patients receiving chemoradiotherapy for rectal cancer was 
not influenced by gender, age, pre-treatment bowel habit or 
body habitus. PTV size, patient positioning and radiotherapy 
delivery technique did not alter the risk. Patients who 
developed G3 toxicity had a larger volume of small bowel 
receiving ≥45 Gy. Based on this, we now routinely calculate 
dose to small bowel, thus identifying patients who are at 
higher risk of developing G3 toxicity and review or change 
the treatment plan, including chemotherapy dose, to 
mitigate this risk. 
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Purpose or Objective: The past decade in rectal cancer 
research has raised questions about complete pathological 
response (pCR) after neoadjuvant therapy. In this context, 
there has been much hype to identify patients with clinical 
complete response (cCR) who could eventually be candidates 
for nonoperative cancer care. So far, experts have published 
stringent criteria to define cCR, which remain to be validated 
with surveillance strategies. The purpose of our study is to 
review pathological mucosal changes after neoadjuvant 
combined chemoradiation therapy (CRT) for rectal cancer. 
 
Material and Methods: This retrospective review was 
conducted in a tertiary referral center. Histopathology 
reports were retrieved for rectal cancer patients treated 
with neoadjuvant CRT. Exclusion criteria included recurrent 
rectal cancer, stage IV disease, rectal cancer in the context 
of IBD or FAP, patient enrollment under clinical trials with 
chemotherapy or other treatment schemes, and patients who 
were not operated. The macroscopic mucosal appearance of 
the specimen was compared with the final pathological 
staging.  
 
Results: Eighty-eight patients met our inclusion criteria and 
had complete staging and pathological data with gross 
mucosal descriptions. These included 59 male and 29 female 
patients with a median age of 63 years (range 29-83). The 
staging proportions were: 3.4% stage cI, 15.9% stage cII, and 
80.7% stage cIII; 93.2% of patients were cT3/cT4 and 75% 
were cN+. Clinical CRM was involved in 30 patients. All 
patients were treated with neoadjuvant CRT consisting of 45 
Gy in 25 fractions to the pelvis with a tumour bed boost of 
5.4 Gy in 3 fractions using 3D conformal radiotherapy; 
chemotherapy was 5-FU based. Total mesorectal excision 
(TME) was performed in all patients. The median time 
between the last day of radiotherapy and surgery was 58 days 
(range 32-308). As a result, 15 patients (17.0%) were staged 
as ypT0N0 (pCR); 12 patients (13.6%) remained CRM+ on 
surgical pathology evaluation. Eighty-seven patients (98.9%) 
had residual mucosal abnormalities incompatible with cCR: 
most changes seen were ulceration and, less often, stenosis. 
Of the 70 patients with microscopic residual tumor, 7 
patients had no macroscopic tumor visualized but an ulcer in 
its place. There was no statistically significant association 
between time from CRT to surgery and pCR. 
 
Conclusion: Most patients undergoing neoadjuvant CRT have 
residual mucosal abnormalities two months after CRT. There 
are needs to define criteria for clinical endoscopic evaluation 
to define cCR. 
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Purpose or Objective: The association between metabolism 
and cancer has been recently emphasized. This study aimed 
to find the prognostic significance of obesity in advanced 
stage rectal cancer patients treated with surgery and 
radiotherapy (RT). 
 
Material and Methods: We retrospectively reviewed the 
medical records of 111 patients who were treated with 
combined surgery and RT for clinical stage II-III (T3 or N+) 
rectal cancer between 2008 and 2014. The prognostic 
significance of obesity (body mass index ≥25 kg/m2, 
according to Asian classification) in local control was 
evaluated. 
 
Results: The median follow-up was 27.3 months (range, 3.3–
82.1 months). Twenty-five patients (22.5%) were classified as 
obese. Treatment failure occurred in 33 patients (29.7%), 
including local failures in 13 patients (11.7%), regional lymph 
node failures in 5, and distant metastases in 24. The 3-year 
local control, recurrence-free survival, and overall survival 
rates were 88.6%, 72.6%, and 87.3%, respectively. Obesity 
(n=25) significantly reduced the local control rate (p=0.049, 
3-year local control 75.8%), especially in women (n=37, 
p=0.026). Segregation of local control was best achieved by 
body mass index of 25.6 as a cutoff value. 
 
Conclusion: Obese rectal cancer patients showed poor local 
control after combined surgery and RT. More effective local 
treatment strategies for obese patients are warranted. 
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Purpose or Objective: To report long-term follow-up data 
and determine the toxicity rate in patients with locally 
advanced rectal cancer (LARC) treated with intensified neo-
adjuvant regimen. 
 
Material and Methods: Patients with histologically proven 
adenocarcinoma of the rectum, stage III-IV, were included 
and treated with a tri-modality approach. Baseline patient 
characteristics are shown in Table 1.  
Intensified neo-adjuvant treatment (CRT) consisted of RT 
total dose of 50.4/54 Gy and concomitant OXP (50 mg/m2/ 
week) and 5-FU (200 mg/m2/ five daily continuous infusion). 
Surgery was planned 7-9 weeks after the end of CRT. 
Adjuvant chemotherapy was recommended in those patients 
with lymph-node metastasis at diagnosis. 
 
Results: One hundred patients (median age 64 years) were 
eligible, between January 2007 and December 2014. Overall, 
the 5-years OS and DFS were 76.4% and 74.5%, respectively. 
Local recurrence was recorded in 9 patients (9%) and 23 
patients (23%) presented distant metastasis. CRT was well 
tolerated, with only 17% grade 3/4 acute toxicity. Twenty-
four patients (24%) had a pathologic complete response (pCR) 
and only 1 patient peri-operative metastasis. The 5-year OS 
rate was 95.7% for patients with pCR and 70.4% without pCR 
(p = 0.0489). The 5-year DFS were 95.7% and 66.7% for pCR 
and no-pCR tumor histology, respectively (p=0.0275) 
(Figure1). 
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Conclusion: Distant metastasis remains the major issue in the 
management of LARC. This study demonstrated improvement 
in pCR, as well as the potential to achieve higher survival 
rates, including DFS. Waiting for randomized phase III trials 
long-term follow-up data, OXP should be considered as 
feasible and valid neo-adjuvant treatment option. The low 
rate of severe toxicity and the effective benefit on pCR and 
peri-operative metastasis support this concomitant CHT 
schedule for LARC. 
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Purpose or Objective: To compare the oncologic outcome of 
total mesorectal excision (TME) to local excision (LE) in 
"early" clinical T3 rectal cancer patients who received 
preoperative radiation therapy.  
 
Material and Methods: "Early" clinical T3 patients, who 
underwent preoperative radiation therapy followed by TME or 
LE at Asan Medical Center between January 2007 and 
December 2013 were retrospectively analyzed. "Early" clinical 
T3 was defined as extramural extension ≤ 5mm, 
circumferential resection margin negative and lateral lymph 
node negative in pretreatment magnetic resonance imaging. 
A one-to-one propensity case-matched analysis was used with 
covariates of baseline characteristics. Local recurrence free 
survival (LRFS), disease free survival (DFS), overall survival 
(OS) were compared between the matched two groups. 
 
Results: A total of 425 patients were identified; 366 
underwent TME and 59 underwent LE. The median follow-up 
period was 47 months. After propensity score-matching, we 
obtained 55 matched pairs. There were no significant 
differences in 3-year LRFS (95.8% vs 94.2%, p=0.927), DFS 
(85.7% vs 90.8%, p=0.473), OS (96.2% vs 100%, p=0.987) 
between TME and LE groups.  
 
Conclusion: In "early" clinical T3 rectal cancer, local excision 
could be a feasible alternative to mesorectal excision after 
preoperative chemoradiation.  
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Purpose or Objective: Cervical intraepithelial neoplasia 
(CIN) and anal squamous cell carcinoma (SCC) are both 
causally associated with human papilloma virus infection 
(HPV). Women who have an HPV infection of the cervix are at 
a higher risk of HPV infection of the anal canal with the same 
HPV subtype(1). The incidence of HPV infection and related 
cancers is increasing in developed nations(2). Until the 
impact of widespread HPV vaccination is manifest, 
presentation with multiple HPV related malignancies will 
become a more common clinical scenario. Our objective was 
to identify the proportion of women with anal cancer who 
had a history of CIN or invasive cervical cancer (ICC) and 
discuss the implications for future practice.  
 
Material and Methods: The medical records and 
histopathology of all consecutive women treated definitively 
for anal cancer at our centre between January 2004 and July 
2015 were reviewed. A case was defined as a woman 
reporting a history of CIN or ICC treated with either a cone 
biopsy or hysterectomy. We extracted treatment details of 
both the anal cancer and CIN or ICC, demographic and 
outcome data. Women with a previous abnormal pap smear 
or low grade cervical dysplasia were not included as a case.  
 
Results: Eight cases (25%) were identified; Stage III (63%), I, 
II, IV (each 12.5%). The women were HIV negative, aged 36-
62 years and diagnosed with HPV positive anal SCC 10-40 
years after their initial diagnosis. Of the remaining 24 
women, Nine had no prior history, Four had a previous 
abnormal pap smear, one a partial hysterectomy for unknown 
reason, two a hysterectomy for benign uterine disease and 
eight no recorded gynaecological history. Seven women had 
definitive chemoradiotherapy and one had sequential 
chemotherapy and radiotherapy (Stage IV). All were alive and 
disease free at follow up. 
 
Conclusion: One quarter of women with anal SCC had a 
previous history of CIN or ICC. This may be an underestimate 
as a gynaecological history was missing in 25% of patients. 
There are several implications for practice: the importance 
of specifically elucidating a history of HPV-related disease 
such as warts, CIN or ICC on history; secondly, to have a high 
index of suspicion when these women present with bowel 
symptoms; third, that this represents a high risk group of 
women who may benefit from participation in anal pap 
screening programs similar to that being investigated in high 
risk men. 
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Purpose or Objective: To test the relationship between 
dosimetric data and pathological response in a series of 52 
patients treated with combined pre-operative 
chemoradiation (CRT) for local advanced rectal cancer.. 
 
Material and Methods: We studied 52 consecutive patients 
treated with pre-operative CRT for locally advanced rectal 
cancer (T3-4N0M0 or any TN+M0, G1-3). Total dose 
prescribed was 44 Gy (2 Gy/fx) (Group 1, n = 10) or 45 Gy 
(1.8 Gy/fx) (Group 2, n = 42), delivered using helical 
Tomotherapy (HT). A concomitant Capecitabine-based 
chemotherapy was also delivered. All patients underwent 
surgery 6 to 8 weeks after the end of CRT. Surgery consisted 
of low anterior resection (LAR) or abdominoperineal excision 
(APR), depending on the tumor distance from anal margin. 
For all patients, we calculated pathological response through 
difference between TNM clinical staging and TNM 
pathological staging such as by pathological Dworak tumor 
regression score (TRG). We tested the relationship between 
pathological response and planning target volume (PTV) 
dosimetric criteria in agreement with ICRU 83 and internal 
guidelines. Selected parameters were: Dmax, Dmin, 
Dmean,D98,D95, D2, V95,V100 ,V107, V110 and target 
volume (cc). Non-parametric statistical analysis (Wilcoxon, U-
Mann-Whitney, Kruskal-Wallis tests) was performed using 
SPSS.21 software (significant level p < 0.05). Planning 
dosimetric data were extracted from patient archives using 
VODCA 5.4.0. 
 
Results: Results: A significant reduction in TNM staging was 
observed post-treatment (p < 0.001 and p < 0.010 for T & N, 
respectively). Furthermore, 3 patients presented a total 
remission (5.8%) and 30 remained stable (57.7%). For Group 
1, average values and standard deviation of Dmean, Dmin and 
Dmax (Gy) were 44.5 ± 0.4, 30.4 ± 3.6, and 47.2 ± 0.3, while 
for Group 2 were 45.1 ± 0.3, 33.1 ± 3.5, and 48.1 ± 0.6. Dose 
